JZ
Johannes Zanzinger
Member Board Of Directors at Centauri Therapeutics Limited
Ulm, Baden-Württemberg
Overview
Johannes Zanzinger is the Global Head of Business Development & Licensing CardioMetabolic Diseases at Boehringer Ingelheim Venture Fund, with a background as a Senior Principal Scientist at Boehringer Ingelheim and experience as a Professor at Ulm University. Notable highlights include leading strategic planning and risk assessment in drug development, as well as investing in innovative pharmaceutical companies like DiogenX and Centauri Therapeutics.
Work Experience
Professor (apl) of Physiology
2011 - Current
Member Board Of Directors
2022
Member Board Of Directors
2020
Member Board Of Directors
2019
Investor @ BI Venture Fund
2019
Global Head, Business Development & Licensing CardioMetabolic Diseases
2009 - 2019
Head, Licensing Metabolic Diseases
2005 - 2009
Senior Principal Scientist, R&D Coordination
2002 - 2005
Board Observer
2021 - 2023
Member Board Of Directors
2019 - 2023
Member Board Of Directors
2020 - 2021
Senior Principle Scientist
1999 - 2002
Discovery Research, in vivo Pharmacology
Pfizer is a biopharmaceutical company that provides affordable access to safe, effective medicines and health care services.
Raised $32,000,000,000.00 from Starboard Value.
Associate Professor of Physiology
1993 - 1999
Education
Dr
1982 - 1991